

# Tadashi Namisaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3907980/publications.pdf>

Version: 2024-02-01

115  
papers

2,529  
citations

218381

26  
h-index

233125

45  
g-index

119  
all docs

119  
docs citations

119  
times ranked

3489  
citing authors

#	ARTICLE	IF	CITATIONS
1	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.	0.6	4
2	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter caseâ€“control study. <i>Journal of Gastroenterology</i> , 2022, 57, 19-29.	2.3	8
3	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	1.9	7
4	Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfaÂ® and VIVAÂ® Systems. <i>Journal of Clinical Medicine</i> , 2022, 11, 434.	1.0	2
5	Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acuteâ€“chronic liver failure development and prognosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2022, 52, 390-400.	1.8	7
6	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 169-180.	0.7	5
7	ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. <i>Journal of Clinical Medicine</i> , 2022, 11, 1835.	1.0	8
8	Clinical Significance of Serum Zinc Levels on the Development of Sarcopenia in Cirrhotic Patients. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 184-193.	0.3	4
9	Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan. <i>Anticancer Research</i> , 2022, 42, 173-183.	0.5	5
10	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy. <i>In Vivo</i> , 2022, 36, 1477-1484.	0.6	0
11	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in dietâ€“induced rat steatohepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1392-1402.	0.4	7
12	Rifaximin enhances the Lâ€“carnitineâ€“mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gutâ€“liverâ€“muscle axis. <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	5
13	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , 2021, 51, 31-38.	1.8	5
14	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4001-4013.	1.6	11
15	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 629.	1.0	1
16	Current status of hepatitis test recognition and an attempt of an efficient screening test in an area with a low implementation rate of hepatitis screening. <i>Acta Hepatologica Japonica</i> , 2021, 62, 89-91.	0.0	1
17	Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolism with inhibition of the LPS/TLR4 signaling pathway. <i>Journal of Nutritional Biochemistry</i> , 2021, 89, 108573.	1.9	58
18	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. <i>Cells</i> , 2021, 10, 575.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021, 54, 371-378.	0.6	16
20	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6921.	1.8	16
21	Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2465.	1.0	6
22	Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 39.	0.7	4
23	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021, 100, e27212.	0.4	10
24	Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. <i>Medicine (United States)</i> , 2021, 100, e27403.	0.4	10
25	Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , 2021, 21, 369.	0.8	2
26	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100526.	1.5	5
27	The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. <i>Journal of Clinical Medicine</i> , 2021, 10, 4838.	1.0	4
28	Association between Equol Production Status and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11904.	1.8	6
29	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 30.	0.8	0
30	Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. <i>World Journal of Gastroenterology</i> , 2021, 27, 8323-8342.	1.4	10
31	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 76-81.	1.4	6
32	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020, 38, 329-334.	0.8	5
33	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7588.	1.8	10
34	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5589.	1.8	21
35	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.	1.0	7
36	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 1467.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	1.0	11
38	Spontaneously ruptured hepatocellular carcinoma in Fontan-associated liver disease: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2092203.	0.2	0
39	Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2â€²-deoxycytidine in Hepatic Stellate Cells. <i>Biology</i> , 2020, 9, 117.	1.3	2
40	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective singleâ€center study. <i>Hepatology Research</i> , 2020, 50, 1101-1105.	1.8	5
41	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020, 8, 925.	1.6	18
42	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2020, 50, 840-852.	1.8	46
43	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020, 12, 1036.	1.7	9
44	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020, 9, 145.	1.5	33
45	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2164.	1.8	12
46	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1926-1933.	1.9	14
47	Association between ADAMTS13 activityâ€™VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 7232-7241.	1.4	11
48	Effect of Lâ€™carnitine on healthâ€™related quality of life in patients with liver cirrhosis. <i>Biomedical Reports</i> , 2020, 13, 1-1.	0.9	7
49	Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 985-995.	0.8	12
50	Novel oral plasminogen activator inhibitorâ€™1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats. <i>Molecular Medicine Reports</i> , 2020, 22, 2948-2956.	1.1	10
51	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	2
52	VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 167.	0.8	20
53	Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study. <i>Nutrients</i> , 2019, 11, 2140.	1.7	4
54	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019, 8, 1153.	1.8	16

#	ARTICLE	IF	CITATIONS
55	Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient L-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2724.	1.8	18
56	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.	1.8	9
57	Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model. <i>Hepatology Research</i> , 2019, 49, 1034-1045.	1.8	5
58	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1015-1025.	1.8	9
59	Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 64.	0.4	3
60	Bezafibrate Improves GLOBE and UKA-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. <i>Hepatology</i> , 2019, 70, 2035-2046.	3.6	83
61	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019, 49, 232-238.	1.8	9
62	Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019, 49, 284-295.	1.8	25
63	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 381-389.	4.5	11
64	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 887-897.	0.8	5
65	ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 424-435.	0.8	8
66	Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 65-73.	4.5	4
67	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. <i>Journal of Gastroenterology</i> , 2018, 53, 1151-1158.	2.3	29
68	Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. <i>Hepatology Research</i> , 2018, 48, 727-734.	1.8	4
69	Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis. <i>Hepatology Research</i> , 2018, 48, E52-E60.	1.8	10
70	Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. <i>International Journal of Cancer</i> , 2018, 142, 1712-1722.	2.3	136
71	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 741-749.	0.6	12
72	Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. <i>BMC Cancer</i> , 2018, 18, 1164.	1.1	5

#	ARTICLE	IF	CITATIONS
73	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409.	1.6	27
74	Efficacy and tolerability of interferon-free regimen for patients with genotype 1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.	0.8	4
75	Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. <i>Scientific Reports</i> , 2018, 8, 12542.	1.6	17
76	Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , 2018, 57, 1087-1092.	0.3	10
77	Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. <i>Cancer Letters</i> , 2018, 434, 120-129.	3.2	31
78	Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. <i>Oncotarget</i> , 2018, 9, 28638-28651.	0.8	18
79	Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. <i>BMC Gastroenterology</i> , 2018, 18, 16.	0.8	6
80	Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis. <i>Hepatology Research</i> , 2017, 47, E178-E186.	1.8	14
81	Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. <i>Hepatology Research</i> , 2017, 47, 854-861.	1.8	30
82	Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2017, 152, 1383-1394.	0.6	115
83	Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. <i>Hepatology Research</i> , 2017, 47, 1317-1328.	1.8	22
84	Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development. <i>Molecular Medicine Reports</i> , 2017, 16, 5752-5758.	1.1	10
85	Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. <i>Oncology Letters</i> , 2017, 14, 3028-3034.	0.8	16
86	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017, 1, 928-945.	2.0	11
87	Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 23-30.	0.8	11
88	Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review). <i>International Journal of Molecular Medicine</i> , 2017, 40, 263-270.	1.8	49
89	Aortic Valve Replacement for the Management of Heyde Syndrome: A Case Report. <i>Journal of Nippon Medical School</i> , 2017, 84, 193-197.	0.3	9
90	A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases. <i>Internal Medicine</i> , 2017, 56, 2589-2594.	0.3	4

#	ARTICLE	IF	CITATIONS
91	Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2017, 23, 6705-6714.	1.4	14
92	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. <i>World Journal of Gastroenterology</i> , 2017, 23, 8355-8366.	1.4	85
93	Gastric granular cell tumor in a youth excised by endoscopic submucosal dissection : A case report and literature review. <i>Acta Gastro-Enterologica Belgica</i> , 2017, 80, 317-319.	0.4	2
94	lpragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. <i>Journal of Gastroenterology</i> , 2016, 51, 1141-1149.	2.3	39
95	Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. <i>Biomedical Reports</i> , 2016, 4, 183-187.	0.9	42
96	Therapeutic effect of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patient with depression. <i>Acta Hepatologica Japonica</i> , 2016, 57, 496-498.	0.0	0
97	Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2016, 51, 162-172.	2.3	30
98	DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. <i>World Journal of Hepatology</i> , 2016, 8, 1194.	0.8	6
99	Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. <i>Molecular Medicine Reports</i> , 2015, 11, 1693-1700.	1.1	62
100	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2033-2040.	1.7	38
101	Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. <i>Journal of Gastroenterology</i> , 2014, 49, 481-491.	2.3	107
102	Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. <i>Journal of Gastroenterology</i> , 2014, 49, 1421-1429.	2.3	17
103	The Effect of Inflammatory Cytokines in Alcoholic Liver Disease. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	183
104	Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. <i>Hepatology Research</i> , 2013, 43, 765-774.	1.8	20
105	Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. <i>Hepatology Research</i> , 2013, 43, 1241-1250.	1.8	25
106	Cross talk between toll-like receptor 4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 723-730.	1.4	41
107	Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G1094-G1104.	1.6	44
108	The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure. <i>Journal of Angiogenesis Research</i> , 2010, 2, 16.	2.9	7

#	ARTICLE	IF	CITATIONS
109	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Research Notes, 2009, 2, 70.	0.6	48
110	Impact of insulin resistance on the progression of chronic liver diseases. International Journal of Molecular Medicine, 2008, 22, 801-8.	1.8	26
111	Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. Journal of Hepatology, 2006, 44, 568-575.	1.8	33
112	A potent angiogenic factor, vascular endothelial growth factor, improves the survival of the on-going acute hepatic failure in rats. Hepatology Research, 2006, 35, 199-203.	1.8	7
113	Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology, 2006, 44, 983-991.	3.6	142
114	Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatology Research, 2003, 27, 51-56.	1.8	35
115	Plasma Endotoxin and Serum Cytokine Levels in Patients With Alcoholic Hepatitis: Relation to Severity of Liver Disturbance. Alcoholism: Clinical and Experimental Research, 2000, 24, 48S.	1.4	157